Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | CPA3 | P15088 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25336942 | 1.00 | FPR2 (0.46) | FPR2CYP1A2PTPN1ALPIPKM | |
| SCHEMBL8202673 | 0.90 | CYP1A2 (0.53) | CYP1A2PTPN1ALPIPKMPTGS1 | |
| SCHEMBL2319694 | 0.90 | CYP1A2 (0.53) | CYP1A2PTPN1ALPIPKMPTGS1 | |
| Hydrochloric Acid SCHEMBL6336814 | 0.89 | CYP1A2 (0.52) | CYP1A2PTPN1ALPIPKMPTGS1 | |
| SCHEMBL27799946 | 0.86 | SLC7A5 (0.49) | CYP1A2PTPN1ALPIPKMPTGS1 | |
| SCHEMBL3800018 | 0.84 | MME (0.49) | FPR2CYP1A2 | |
| SCHEMBL18039536 | 0.84 | MME (0.49) | FPR2CYP1A2 | |
| SCHEMBL21295478 | 0.84 | EPOR (0.43) | FPR2 | |
| SCHEMBL21295477 | 0.84 | EPOR (0.43) | FPR2 | |
| Hydrochloric Acid SCHEMBL21295474 | 0.83 | EPOR (0.42) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416280-A1 | METHOD FOR PRODUCING 4-BORONO-L-PHENYLALANINE AND INTERMEDIATE THEREOF | STELLA PHARMA CORPORATION (JP) | 2023-12-28 | — | — | US | disclosed |
| EP-4223762-A1 | METHOD FOR PRODUCING 4-BORONO-L-PHENYLALANINE AND INTERMEDIATE THEREOF | Stella Pharma Corporation (JP) | 2023-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416280-A1 | METHOD FOR PRODUCING 4-BORONO-L-PHENYLALANINE AND INTERMEDIATE THEREOF | PAH, BCAT2, BCAT1 | FPR2 2193/4885CYP1A2 197/4885PTPN1 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.